首页|期刊导航|中国合理用药探索|贝伐珠单抗治疗复发性卵巢癌的剂量优化与安全性评价

贝伐珠单抗治疗复发性卵巢癌的剂量优化与安全性评价OA

Dose Optimization and Safety Evaluation of Bevacizumab in Recurrent Ovarian Cancer

中文摘要英文摘要

目的:探讨贝伐珠单抗用于复发性卵巢癌治疗的合理剂量方案及安全性,为临床用药提供循证依据.方法:回顾性分析2022~2023年本院妇科收治的150例复发性卵巢癌患者的临床资料,根据贝伐珠单抗用药剂量分为低剂量组(5 mg/kg,q2w)、中剂量组(10 mg/kg,q2w)和高剂量组(15 mg/kg,q3w),每组 50 例.在治疗 6 周后进行首次疗效评估,随后每 6 周复评一次,直至疾病进展或出现不可耐受毒性.采用Logistic回归分析影响患者疗效的独立因素.比较三组患者的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)及不良反应发生率.结果:中剂量组ORR(64.0%)、DCR(88.0%)和高剂量组ORR(66.0%)、DCR(90.0%)均高于低剂量组(42.0%、68.0%)(P<0.05);中剂量组与高剂量组比较无统计学差异(P>0.05).中剂量组中位PFS(8.5个月)和高剂量组中位PFS(8.8个月)均长于低剂量组(6.2个月)(P<0.05);中剂量组与高剂量组比较无统计学差异(P>0.05).高剂量组高血压(36.0%)、蛋白尿(28.0%)发生率高于低剂量组(14.0%、8.0%)和中剂量组(18.0%、12.0%)(P<0.05);三组胃肠道反应、出血、疲劳发生率比较无统计学差异(P>0.05).多因素Logistic回归分析显示,以低剂量组为参照,中剂量组(OR=2.310,95%CI:1.240~4.320,P=0.009)和高剂量组(OR=2.450,95%CI:1.320~4.560,P=0.004)均与治疗有效(CR+PR)的较高发生可能性独立相关.结论:10 mg/kg、q2w的贝伐珠单抗方案在复发性卵巢癌治疗中的疗效与15 mg/kg、q3w方案相当且优于5 mg/kg、q2w方案,同时高血压和蛋白尿发生率低于高剂量组.本研究中该方案综合疗效与安全性较优,可为临床剂量选择提供参考,但仍需前瞻性研究进一步验证.

Objective:To investigate an appropriate bevacizumab dosing regimen and its safety in the treatment of recurrent ovarian cancer,thereby providing evidence to guide clinical use.Methods:Clinical data from 150 patients with recurrent ovarian cancer treated in the Department of Gynecology at our hospital between 2022 and 2023 were retrospectively analyzed.According to the bevacizumab dose,patients were divided into the low-dose group(5 mg/kg,q2w),medium-dose group(10 mg/kg,q2w),and high-dose group(15 mg/kg,q3w),with 50 patients in each group.The first efficacy assessment was performed after 6 weeks of treatment.Efficacy was subsequently reassessed every 6 weeks until disease progression or intolerable toxicity.Logistic regression analysis was used to identify independent factors influencing treatment efficacy.The objective remission rate(ORR),disease control rate(DCR),progression free survival(PFS),and incidence of adverse reactions were compared among the three groups.Results:The ORR and DCR were 64.0%and 88.0%in the medium-dose group and 66.0%and 90.0%in the high-dose group,respectively,and were higher than the corresponding rates in the low-dose group(42.0%and 68.0%;P<0.05).No significant differences in ORR or DCR were observed between the medium-and high-dose groups(P>0.05).Median PFS was longer in the medium-dose group(8.5 months)and high-dose group(8.8 months)than in the low-dose group(6.2 months;P<0.05),with no significant difference between the medium-and high-dose groups(P>0.05).The incidences of hypertension and proteinuria in the high-dose group(36.0%and 28.0%,respectively)were higher than those in the low-dose group(14.0%and 8.0%)and medium-dose group(18.0%and 12.0%;P<0.05).No significant differences in the incidences of gastrointestinal reactions,bleeding,or fatigue were observed among the three groups(P>0.05).Multivariable Logistic regression analysis,with the low-dose group as the reference,showed that the medium-dose group(OR=2.310,95%CI:1.240~4.320,P=0.009)and high-dose group(OR=2.450,95%CI:1.320~4.560,P=0.004)were independently associated with a higher likelihood of treatment effectiveness(CR+PR).Conclusion:The 10 mg/kg,q2w bevacizumab regimen provided efficacy comparable to the 15 mg/kg,q3w regimen and superior to the 5 mg/kg,q2w regimen,while being associated with lower incidences of hypertension and proteinuria than the high-dose regimen.In this study,the comprehensive efficacy and safety of this regimen were relatively good,which can provide reference for clinical dose selection,but further prospective research is still needed for verification.

葛银;陈继维;王菲

郑州大学第一附属医院妇科一病区,郑州 450000郑州大学第一附属医院妇科一病区,郑州 450000郑州大学第一附属医院妇科一病区,郑州 450000

医药卫生

复发性卵巢癌贝伐珠单抗用药剂量客观缓解率无进展生存期安全性

recurrent ovarian cancerbevacizumabdoseobjective response rateprogression free survivalsafety

《中国合理用药探索》 2026 (8)

28-34,7

10.3969/j.issn.2096-3327.2026.08.005

评论